VASOPRESSIN IN SODIUM CHLORIDE 0.9% Drug Patent Profile
✉ Email this page to a colleague
When do Vasopressin In Sodium Chloride 0.9% patents expire, and when can generic versions of Vasopressin In Sodium Chloride 0.9% launch?
Vasopressin In Sodium Chloride 0.9% is a drug marketed by Baxter Hlthcare Corp and Long Grove Pharms and is included in two NDAs.
The generic ingredient in VASOPRESSIN IN SODIUM CHLORIDE 0.9% is vasopressin. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vasopressin In Sodium Chloride 0.9%
A generic version of VASOPRESSIN IN SODIUM CHLORIDE 0.9% was approved as vasopressin by AM REGENT on August 3rd, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VASOPRESSIN IN SODIUM CHLORIDE 0.9%?
- What are the global sales for VASOPRESSIN IN SODIUM CHLORIDE 0.9%?
- What is Average Wholesale Price for VASOPRESSIN IN SODIUM CHLORIDE 0.9%?
Summary for VASOPRESSIN IN SODIUM CHLORIDE 0.9%
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 251 |
| DailyMed Link: | VASOPRESSIN IN SODIUM CHLORIDE 0.9% at DailyMed |
Recent Clinical Trials for VASOPRESSIN IN SODIUM CHLORIDE 0.9%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Basel, Switzerland | Phase 2 |
| Kingman Regional Medical Center | Phase 4 |
| University of Alberta | Phase 1 |
Pharmacology for VASOPRESSIN IN SODIUM CHLORIDE 0.9%
| Physiological Effect | Decreased Diuresis Vasoconstriction |
US Patents and Regulatory Information for VASOPRESSIN IN SODIUM CHLORIDE 0.9%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | vasopressin | SOLUTION;INTRAVENOUS | 217569-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Long Grove Pharms | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | vasopressin | SOLUTION;INTRAVENOUS | 217766-002 | Jul 11, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Baxter Hlthcare Corp | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | vasopressin | SOLUTION;INTRAVENOUS | 217569-002 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
